Patents by Inventor Frank S. MENNITE

Frank S. MENNITE has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20180369245
    Abstract: Disclosed herein, in part, are heteroaromatic compounds and methods of use in treating neuropsychiatric disorders, e.g., schizophrenia and major depressive disorder. Pharmaceutical compositions and methods of making heteroaromatic compounds are provided. The compounds are contemplated to modulate the NMDA receptor.
    Type: Application
    Filed: December 9, 2016
    Publication date: December 27, 2018
    Applicant: Cadent Therapeutics, Inc.
    Inventors: David R. ANDERSON, Robert A. VOLKMANN, Frank S. MENNITE, Christopher FANGER
  • Publication number: 20180362541
    Abstract: Disclosed herein, in part, are heteroaromatic compounds and methods of use in treating neuropsychiatric disorders, e.g., schizophrenia and major depressive disorder. Pharmaceutical compositions and methods of making heteroaromatic compounds are provided. The compounds are contemplated modulate the NMDA receptor.
    Type: Application
    Filed: December 9, 2016
    Publication date: December 20, 2018
    Inventors: David R. ANDERSON, Robert A. VOLKMANN, Frank S. MENNITE, Christopher FANGER
  • Publication number: 20180360837
    Abstract: Disclosed herein, in part, are methods of treating neurological disorders, e.g., schizophrenia and major depressive disorder, comprising administering an effective amount of a disclosed heterocyclic compound. Pharmaceutical compositions and methods of making heteroaromatic compounds are provided. The compounds are contemplated to modulate the NMDA receptor.
    Type: Application
    Filed: December 9, 2016
    Publication date: December 20, 2018
    Inventors: David R. ANDERSON, Robert A. VOLKMANN, Frank S. MENNITE, Christopher FANGER